Investors Research Corp’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $440K | Hold |
12,974
| – | – | 0.08% | 187 |
|
|
2026
Q1 | $391K | Sell |
12,974
-300
| -2% | -$9.65K | 0.07% | 202 |
|
|
2025
Q4 | $414K | Sell |
13,274
-10,617
| -44% | -$262K | 0.08% | 223 |
|
|
2025
Q3 | $483K | Hold |
23,891
| – | – | 0.09% | 205 |
|
|
2025
Q2 | $400K | Hold |
23,891
| – | – | 0.08% | 223 |
|
|
2025
Q1 | $367K | Hold |
23,891
| – | – | 0.08% | 225 |
|
|
2024
Q4 | $527K | Sell |
23,891
-300
| -1% | -$5.46K | 0.12% | 189 |
|
|
2024
Q3 | $436K | Hold |
24,191
| – | – | 0.1% | 218 |
|
|
2024
Q2 | $393K | Sell |
24,191
-375
| -2% | -$5.78K | 0.09% | 233 |
|
|
2024
Q1 | $347K | Sell |
24,566
-850
| -3% | -$10.7K | 0.08% | 262 |
|
|
2023
Q4 | $265K | Hold |
25,416
| – | – | 0.06% | 286 |
|
|
2023
Q3 | $259K | Hold |
25,416
| – | – | 0.07% | 284 |
|
|
2023
Q2 | $191K | Sell |
25,416
-200
| -0.8% | -$1.62K | 0.05% | 334 |
|
|
2023
Q1 | $227K | Sell |
25,616
-225
| -0.9% | -$2.23K | 0.06% | 309 |
|
|
2022
Q4 | $236K | Sell |
25,841
-225
| -0.9% | -$1.96K | 0.06% | 296 |
|
|
2022
Q3 | $210K | Hold |
26,066
| – | – | 0.06% | 297 |
|
|
2022
Q2 | $196K | Sell |
26,066
-300
| -1% | -$2.61K | 0.06% | 316 |
|
|
2022
Q1 | $248K | Hold |
26,366
| – | – | 0.07% | 301 |
|
|
2021
Q4 | $211K | Sell |
26,366
-350
| -1% | -$3.16K | 0.06% | 299 |
|
|
2021
Q3 | $260K | Hold |
26,716
| – | – | 0.09% | 264 |
|
|
2021
Q2 | $264K | Hold |
26,716
| – | – | 0.09% | 257 |
|
|
2021
Q1 | $308K | Sell |
26,716
-75
| -0.3% | -$860 | 0.12% | 242 |
|
|
2020
Q4 | $259K | Sell |
26,791
-1,250
| -4% | -$12K | 0.1% | 277 |
|
|
2020
Q3 | $253K | Sell |
28,041
-250
| -0.9% | -$2.65K | 0.12% | 245 |
|
|
2020
Q2 | $349K | Sell |
28,291
-775
| -3% | -$8.77K | 0.18% | 189 |
|
|
2020
Q1 | $261K | Sell |
29,066
-250
| -0.9% | -$2.56K | 0.16% | 214 |
|
|
2019
Q4 | $287K | Sell |
29,316
-250
| -0.8% | -$2.23K | 0.13% | 235 |
|
|
2019
Q3 | $203K | Sell |
29,566
-25
| -0.1% | -$192 | 0.1% | 252 |
|
|
2019
Q2 | $273K | Sell |
29,591
-425
| -1% | -$5.13K | 0.14% | 203 |
|
|
2019
Q1 | $471K | Sell |
30,016
-300
| -1% | -$5.29K | 0.25% | 136 |
|
|
2018
Q4 | $467K | Buy |
30,316
+250
| +0.8% | +$5.13K | 0.33% | 130 |
|
|
2018
Q3 | $648K | Sell |
30,066
-551
| -2% | -$12.8K | 0.37% | 104 |
|
|
2018
Q2 | $745K | Buy |
30,617
+475
| +2% | +$9.69K | 0.43% | 70 |
|
|
2018
Q1 | $515K | Sell |
30,142
-700
| -2% | -$13.7K | 0.31% | 124 |
|
|
2017
Q4 | $584K | Buy |
+30,842
| New | +$464K | 0.36% | 100 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Investors Research Corp's TEVA Position: Q2 2026 in Review
Investors Research Corp held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 12,974 shares worth $440K. The position accounts for 0.08% of the portfolio, ranked #187.
Investors Research Corp first reported a position in TEVA in Q4 2017 and has held it in 35 quarters since. The position peaked at $745K in Q2 2018. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Investors Research Corp held 12,974 shares of Teva Pharmaceuticals worth $440K as of Q2 2026.
- Investors Research Corp left its Teva Pharmaceuticals share count unchanged in Q2 2026.
- Teva Pharmaceuticals made up 0.08% of Investors Research Corp's portfolio in Q2 2026, its #187 holding.
- Investors Research Corp first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Investors Research Corp's Teva Pharmaceuticals position peaked at $745K in Q2 2018.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.